I. RESTATEMENT (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Research and development expenses	$ 6,578,618	$ 4,151,983	$ 10,126,875	$ 8,844,891
Total operating expenses	7,923,732	5,829,779	12,878,998	11,157,288
Operating loss	(7,906,557)	(5,797,004)	(12,844,565)	(11,103,537)
Interest income (expense), net	(471,234)	(464,796)	(940,385)	(948,489)
Net Loss	$ (8,426,491)	$ (8,855,530)	$ (4,905,338)	$ (6,522,796)
Net income per share - basic			$ (0.74)	$ (1.43)
Net income per share - diluted			$ (0.78)	(1.43)
Net income per share - basic and diluted	$ (1.15)	$ (1.87)		$ (1.43)
Previously Reported
Research and development expenses	$ 7,055,217	$ 4,628,582	$ 11,080,073	$ 9,798,089
Total operating expenses	8,400,331	6,306,378	13,832,196	12,110,486
Operating loss	(8,383,156)	(6,273,603)	(13,797,763)	(12,056,735)
Interest income (expense), net	22,367	22,478	45,464	24,463
Net Loss	$ (8,409,489)	$ (8,844,855)	$ (4,872,687)	$ (6,503,042)
Net income per share - basic			$ (0.73)	$ (1.43)
Net income per share - diluted			$ (0.78)	$ (1.43)
Net income per share - basic and diluted	$ (1.15)	$ (1.87)
Adjustment
Research and development expenses	$ (476,599)	$ (476,599)	$ (953,198)	$ (953,198)
Total operating expenses	(476,599)	(476,599)	(953,198)	(953,198)
Operating loss	476,599	476,599	953,198	953,198
Interest income (expense), net	(493,601)	(487,274)	(985,849)	(972,952)
Net Loss	$ (17,002)	$ (10,675)	$ (32,651)	$ (19,754)